Evidence map›Paper›PMID 35935862›Full record

ArticleFrontiers in pharmacology2022

Isoliensinine Suppresses Osteoclast Formation Through NF-κB Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss.

Huijiang Liu, Ronghe Gu, Qian Huang, Yun Liu, Chong Liu, Shijie Liao, Wenyu Feng, Tianyu Xie, Jinmin Zhao, Jiake Xu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Huijiang LiuDepartment of Orthopedics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ronghe GuDepartment of Orthopedics, The First People's Hospital of Nanning, Nanning, China.
Qian HuangDepartment of Orthopedics, The First People's Hospital of Nanning, Nanning, China.
Yun LiuDepartment of Orthopedics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Chong LiuDepartment of Orthopedics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shijie LiaoDepartment of Orthopedics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Wenyu FengDepartment of Orthopedics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Tianyu XieDepartment of Orthopedics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jinmin ZhaoDepartment of Orthopedics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jiake XuSchool of Biomedical Sciences, University of Western Australia, Perth, WA, Australia.
Qian LiuGuangxi Key Laboratory of Regenerative Medicine, Orthopedic Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xinli ZhanDepartment of Orthopedics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CNUniversity of Western Australia · AUFirst People's Hospital of Nanning · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis is among the major contributors of pathologic fracture in postmenopausal women, which is caused by the bone metabolic disorder owing to the over-activation of osteoclasts. Inhibition of osteoclast differentiation and maturation has become a mainstream research interest in the prevention of osteoporosis. Isoliensinine (Iso) is a dibenzyl isoquinoline alkaloid with antioxidant, anti-inflammatory, and anti-cancer activities. However, whether it can be used as a potential treatment for osteoporosis remains undiscovered. Here, we investigated whether Iso might suppress the differentiation of osteoclasts

Indexed as

isoliensinineNF-κB pathwayosteoclastosteoporosisreceptor activator of nuclear factor-κB ligand (RANKL)

Identifiers

PMID35935862
PMCPMC9353689
OpenAlexW4286716911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.